Flash Player 9.0.0 is required for the Video Gallery.
Get Adobe Flash Player.
Robert H. Brown, Jr., MD, sat down with Neurology Today Editor-in-chief Steven P. Ringel, MD, at the 2013 American Neurological Association (ANA) annual meeting in New Orleans to discuss his goals for the ANA during his tenure. Dr. Brown said the ANA will “continue the incredible effort to get young people” involved, reach out to colleagues in pharma, and expand their international outreach — in hopes of furthering the ANA’s mission of understanding and treating neurological diseases. Dr. Brown also discussed the looming changes in U.S. health care and research — and how the ANA will respond.
Neurology Today editors interview Kristina Simonyan, MD, PhD, associate professor of neurology and otolaryngology at the Icahn School of Medicine at Mount Sinai, and Serena Bianchi, PhD, a post-doctoral fellow in Dr. Simonyan’s laboratory, about their imaging studies showing structural differences between different phenotypes and genotypes of spasmodic dysphonia.
Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, and Associate Editor Robert Holloway, MD, MPH, FAAN, discuss the challenges of measuring the value of neurodiagnostic tests, with a dearth of available data on efficacy.
Read the full story in Neurology Today: http://bit.ly/NT-ANADiagnosticTests.
A meta-analysis of 5 trials found that the procedure was more effective for stroke, the sooner it was performed, but remained effective up to 7.3 hours after symptom onset – significantly longer than the current guideline window of 6 hours. Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, and Associate Editor Robert Holloway, MD, MPH, FAAN, discuss what the findings mean for stroke treatment and minimizing time to reperfusion.
Read the full story in Neurology Today: http://bit.ly/NT-ANAEndovascular.
A 5-year follow-up study found that deep brain stimulation (DBS) of the subthalamic nucleus improved motor function for people with early-stage Parkinson’s disease compared to medical treatment alone. The study’s principal investigator David Charles, MD, FAAN, professor and vice chairman of neurology at Vanderbilt Neuroscience Institute, discusses the advantages and complications of treating patients in early stages of the disease with the Neurology Today editors.
Read the full story in Neurology Today: http://bit.ly/NT-DBSEarlyParkinsons.
Friend's E-mail is Invalid
Your message has been successfully sent to your friend.